A British Columbia court has given its final approval to Coeur Mining's planned acquisition of New Gold, moving the deal that will create a North American precious metals giant one step closer to its expected H1 2026 closing.
A new federal loan aims to help the revived Buell Motorcycle Company scale production of its high-performance Super Cruiser, testing whether niche innovation can find a sustainable path in a competitive market.
A Dominus and Cheyne Capital partnership wins City of London approval to convert the Grade II-listed Ibex House into a 382-room hotel, slated for a late 2028 opening, complete with a hospitality academy and restored pub.
Amazon's recent workforce reductions, bringing total corporate cuts to 30,000, reflect a broader shift in how layoffs are perceived. No longer framed as a sign of failure, they are increasingly presented as a strategic, forward-looking move to streamline operations and focus on priorities like AI, a narrative that resonates with investors despite the human impact.
A growing movement to eliminate state income taxes is gaining momentum, backed by the White House. However, a new analysis warns that replacing lost revenue may require significantly higher sales taxes than proponents claim, forcing a fundamental choice: accept steeper consumption taxes or shrink the size of government.
A terminal diagnosis brings immense emotional strain, but the looming question of outstanding debt adds a crushing financial burden for families. We examine the legal realities of debt inheritance, offering crucial strategies for protection and peace of mind.
Amgen has transferred full rights for the atopic dermatitis drug rocatinlimab back to Kyowa Kirin, clearing the path for the Japanese firm to pursue US approval by 2026. The move comes despite the drug meeting all trial endpoints, reflecting Amgen's portfolio reprioritization and a tempered market outlook for the OX40 inhibitor class.
South Korean financial regulators are deploying advanced artificial intelligence to monitor cryptocurrency transactions in real-time, aiming to detect and preempt market manipulation. The move, part of a broader crackdown, could see violators face severe penalties, including life imprisonment.
As the housing market evolves, a three-digit number remains the decisive factor for mortgage seekers. The latest FICO scoring model now considers rental history, potentially opening doors for millions of aspiring homeowners.
Cleveland-based KeyCorp (KEY) is riding a wave of positive analyst sentiment following a strong earnings beat, with its stock performance significantly outpacing broader market indices. The bank's diversified model and robust capital returns are fueling optimism for sustained growth.
A coalition of licensed marijuana companies in Missouri has launched a wave of lawsuits against dozens of smoke shops, alleging they are exploiting a legal gray area to sell intoxicating THCA hemp flower, undermining the state's regulated market and creating unfair competition.
Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.
As mortgage rates fluctuate and ambitious policy ideas emerge, economists warn that financing tweaks cannot solve the core issue: a chronic shortage of homes.
Seaport Research analyst Scott Graham lowered Badger Meter's price target to $220 from $255, citing a slower sales pace in early 2025. The firm maintains a Buy rating, anticipating a stronger second half. The water technology company recently reported record annual sales and profits.
Truist Securities raises its price target on Huntington Bancshares (HBAN) following a robust Q4 performance, as the regional bank forecasts record interest income growth and benefits from improving industry tailwinds.
Insurance brokerage giant Arthur J. Gallagher reported robust fourth-quarter profit growth, driven by resilient demand. However, Truist Securities has lowered its price target on the stock, citing valuation pressures across the property & casualty brokerage sector.
UBS analyst Peter Grom increased his price target for Kimberly-Clark (KMB) to $110, citing steady core performance despite lingering Kenvue-related uncertainties, after the consumer goods giant reported better-than-expected quarterly profit driven by cost discipline and resilient demand.
Stifel Nicolaus lowered its price target on Altria Group (MO) by $4 to $68, citing higher-than-expected operating costs. Despite near-term headwinds, the firm reaffirmed its Buy rating, pointing to the tobacco giant's resilient dividend profile and long-term earnings guidance.
Despite a partial recovery, Pfizer's stock remains significantly below its pandemic-era peak. As 2026 approaches, the pharmaceutical giant confronts a critical juncture defined by looming patent expirations, a high-stakes catch-up effort in the lucrative GLP-1 market, and a dividend under pressure.
CIBC lowers OpenText's price target to $37, citing softer guidance and a watchful stance on the company's planned divestiture of non-core assets to sharpen its AI focus.
